Adstiladrin (nadofaragene firadenovec-vncg) prior authorization — Non‑muscle invasive bladder cancer
Customize your policy alerts
Sign up for AvMed Policy Pub. 100-2 alerts
Get alerted when Policy Pub. 100-2 changes without checking for updates manually.
Monitor payer policy activity
Requirements and clinical criteria for prior authorization of Adstiladrin (J9029) for treatment of non‑muscle invasive bladder cancer in AvMed members; intended for prescribing providers and facility staff submitting PA/step-edit requests.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.